They sold their company to Boston Scientific and then reacquired the technology years later – the unique story of NuCryo Vascular

NuCryo Vascular GM      Kevin Beedon Welcome to the Medsider interview series, a special new feature at MassDevice, which will appear regularly. All interviews are conducted by Scott Nelson, Founder of Medsider and Partnership Lead at Touch Surgery. We hope you enjoy them! Because of diminishing margins, a lot of major medical device companies continue to add products to their sales bag in hopes of meeting top-line revenue goals. But successfully selling the entire bag can be challenging. When the bag gets too big, a typical sales force will usually focus only on products that generate the most revenue. So what about the products that don’t product much revenue? Well, they’re sometimes just lost in the dust. In the following interview with Kevin Beedon, General Manager of NuCryo Vascular, we learn how their team is taking advantage of this very scenario as they look to commercialize the newly redesigned PolarCath device. The following conversation is based on an audio interview with Scott Nelson and Kevin Beedon. Scott is the Founder of Medsider and leads partnerships at Touch Surgery. Scott Nelson:            Let’s start with NuCryo because it’s an an interesting story. And by the way, congrats on your recent 510(k) clearance. The cryo-catheter device that you’re commercializing has a storied history with the likes of Dr. James Joye, who initially founded CryoVascular Systems, the acquisition by Boston Scientific, and so on. Can you provide a ...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Business/Financial News NuCryo Vascular Source Type: news